Stemline Therapeutics (STML) Issues Encouraging Top-Line Data Update on Pivotal SL-401 Trial
Tweet Send to a Friend
Stemline Therapeutics (NASDAQ: STML) announced top-line results from the lead-in stage of its ongoing SL-401 pivotal trial in blastic plasmacytoid ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
